Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus

International Journal of Gynecological Pathology

Volumn 23, Issue 3, 2004, Pages 234-240

  Watanabe, Jun ^a   Nishizaki, Ritsuko ^b   Jobo, Toshiko ^a   Kamata, Yuko ^b   Hata, Hiroki ^a   Nishimura, Yukari ^b   Fujisawa, Takeshi ^b   Okayasu, Isao ^a   Kuramoto, Hiroyuki ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Endometrial adenocarcinoma; Endometrial hyperplasia; Endometrium; Immunohistochemistry; p14ARF; Tumor suppressor gene

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; ESTROGEN RECEPTOR; GENE PRODUCT; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL CYCLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL CYCLE PROTEINS; DNA, NEOPLASM; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 3042698218     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000130050.27266.9a     Document Type: Article

References (31)

1. ARF, participates in regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
2. Weber JD, Taylor LJ, Roussel MF, et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6.
3. ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001;61:2816-21.
4. ARF tumor suppressor. Genes Dev 1998;12:2434-42.
5. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
6. ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125-6.
7. ARF. Cell 1997;91:649-59.
8. Sano T, Hikino T, Xue Q, et al. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma. Pathol Int 2000;50:709-16.
9. Xue Q, Sano T, Kashiwabara K, et al. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol Int 2002;52:103-9.
10. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998;17:2779-85.
11. Hashiguchi Y, Tsuda H, Yamamoto K, et al. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001;32:988-96.
12. Xue Q, Sano T, Kashiwabara K, et al. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of Lung. Jpn J Cancer Res 2001;92:285-92.
13. KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 2001;92:1177-89.
14. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
15. Cauley JA, Gutai JP, Kuller LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
16. Jobo T, Tateoka K, Kuramoto H. Study on the long-term follow-up of endometrial hyperplasia. Int J Clin Oncol 1996;1:163-9.
17. Maeda K, Tsuda H, Hashiguchi Y, et al. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002;33:386-91.
18. FIGO news. Corpus cancer staging. Int. J. Gynecol. Obstet 1989;28:189-93.
19. Akaboshi M, Watanabe J, Fujisawa T, et al. Immunohistochemical expression of cdk2 and Ki-67 in human endometrial carcinoma. J Jpn Soc Clin Cytol 2001;40:121-7.
20. Kyushima N, Watanabe J, Hata H, et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 2002;128:307-12.
21. Watanabe J, Kamata Y, Kanai T, et al. Expression of cell cycle regulators in endometrial adenocarcinoma. In: Kuramoto H, ed. Cell and Molecular Biology of Endometrial Carcinoma. Tokyo: Springer-Verlag, 2003:93-106.
22. Kato N, Watanabe J, Jobo T, et al. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol. 2003;129:222-6.
23. Watanabe J, Sato H, Kanai T, et al. Paradoxical Expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus: correlation with proliferation and clinicopathological parameters. Br J Cancer 2002;87:81-5.
24. Fijisawa T, Watanabe J, Akaboshi M, et al. Immunohistochemical study on VEGF expression in endometrial carcinoma: comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 2001;127:668-74.
25. Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2003;
26. Uchida T, Wada C, Shitara T, et al. Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer. Br J Cancer 1993;68:751-5.
27. Orita M, Suzuki Y, Sekiya T, et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
28. Ohkawara S, Jobo T, Sato R, et al. Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia. Eur J Gynaecol Oncol 2000;21:573-7.
29. Shahnavaz SA, Bradley G, Regezi JA, et al. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. Cancer Res 2001;61:2371-5.
30. INK4a methylation and p53 mutational status. Cancer Res 2000;60:129-33.
31. Tannapfel A, Busse C, Weinans L, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001;20:7104-9.